Article By:
ChinaBio® Today
Saturday, February 13, 2021 12:37 PM EDT
Adagene, a Suzhou immunoncology biopharma, completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Adagene has a market capitalization of about $1 billion.